Injectable Exosome-Filled Hydrogel Rebuilds Gum Bone by Silencing an Inflammatory Pathway

Periodontitis is one of the most common chronic diseases on the planet, and one of the most stubborn. The condition, in which bacterial plaque triggers an immune storm that slowly dissolves the alveolar bone anchoring the teeth, affects hundreds of millions of people and is tightly linked to diabetes and cardiovascular disease. Standard care—mechanical debridement plus antibiotics—can slow the destruction, but it cannot rebuild what has been lost, and repeated antibiotic use fuels resistance. Now a team in China reports a injectable material that tackles both sides of the problem at once: it calms inflammation and coaxes new bone to grow, by delivering regenerative nanoparticles in a light-cured gel that stays put exactly where it is needed.

The study, published in the Journal of Cellular and Molecular Medicine, centres on exosomes—nanoscale vesicles that cells naturally secrete to communicate with one another. These vesicles ferry microRNAs, transcription factors and proteins between cells, and have become one of the most hotly pursued tools in regenerative medicine. Compared with transplanting living stem cells, exosomes are less immunogenic, more stable, and far easier to store and ship, making them an attractive cell-free therapy. The researchers sourced theirs from human umbilical cord blood, a material collected non-invasively after rigorous prenatal screening that is otherwise discarded as medical waste. Cord blood vesicles are known to be more concentrated and biologically active than those circulating in adult peripheral blood, and previous work has shown they can accelerate wound healing and bone repair.

But exosomes have an Achilles heel: injected alone, they are cleared from the body within hours, never maintaining a therapeutic concentration at the lesion. The team’s answer was a delivery vehicle built from two photocrosslinkable polymers—gelatin methacryloyl (GelMA) and sodium alginate methacryloyl (AlgMA)—mixed into a prepolymer solution with the vesicles and a photoinitiator called LAP. The mixture is fluid enough to inject into a periodontal pocket, then solidifies in 30 seconds under 405-nanometre blue light, forming a soft scaffold the authors call GA-Exos. Scanning electron microscopy revealed a loose, porous network with an average pore size of roughly 12 micrometres, while infrared spectroscopy confirmed the covalent crosslinking of both polymers.

Mechanical testing showed why the alginate component matters. Pure GelMA gels are biocompatible but floppy—poorly suited to the chewing forces of the mouth. The composite gel reached a peak compressive stress of 58.78 kilopascals at 60% strain, nearly double the 32.44 kilopascals of GelMA alone, and rheology confirmed a stable, elastic-dominant network after curing. Crucially, loading the exosomes did not disturb the gel’s water uptake or degradation kinetics: both GA and GA-Exos swelled to roughly 43% within about two days and lost around 46–47% of their dry mass over 21 days in physiological conditions. Release assays showed the vesicles trickling out gradually—48.1% of the payload by day 3 and 82.6% by day 21—exactly the sustained profile needed to keep regenerative signalling active through the weeks of healing.

In laboratory dishes, the material proved both safe and bioactive. Live/dead staining and CCK-8 assays found no cytotoxicity toward rat bone marrow mesenchymal stem cells (BMSCs), and the exosome-loaded gel actually boosted stem cell proliferation at 48 hours, while the bare gel did not. Fluorescently labelled vesicles were visibly internalised by the stem cells within 12 hours, accumulating around the nuclei. Scratch assays showed that exosome concentrations of 20 and 30 micrograms per millilitre significantly accelerated cell migration. Most strikingly, standard osteogenic assays—alkaline phosphatase staining at days 3 and 7, and Alizarin Red staining of mineralised nodules at days 14 and 21—showed that GA-Exos drove the stem cells firmly down the bone-forming pathway, with the genes RUNX2, ALP and OPN and their corresponding proteins all significantly upregulated.

The real test came in living animals. The team induced periodontitis in rats by tying silk ligatures around the first molars and injecting bacterial lipopolysaccharide (LPS) locally twice a week for four weeks, producing the classic signs of gum swelling, bleeding, loosened teeth and radiolucent bone loss on cone-beam CT scans. After debridement, the animals received injections of GA-Exos, bare GA gel, or saline into the periodontal pockets, cured in place with blue light. Four weeks later, the GA-Exos group showed markedly reduced gingival inflammation, with significantly lower expression of the pro-inflammatory cytokines TNF-α and IL-1β in gum tissue.

Bone imaging told an equally compelling story. Micro-computed tomography at 17-micrometre resolution revealed that the GA-Exos group had significantly higher bone volume fraction, greater mean CT values, thicker and more numerous trabeculae, and a shorter distance between the alveolar bone crest and the cementoenamel junction—the gold-standard measure of periodontal bone height. Histology backed this up: haematoxylin and eosin sections showed less inflammatory infiltration and clear evidence of newly formed periodontal tissue and blood vessels, while tartrate-resistant acid phosphatase (TRAP) staining revealed far fewer bone-resorbing osteoclasts than in the control groups. In other words, the treatment simultaneously rebuilt bone and shut down the cellular machinery that destroys it.

To find out how, the researchers turned to transcriptomics. Messenger RNA sequencing of exosome-treated versus untreated cells identified 1,381 differentially expressed genes—440 upregulated and 941 downregulated. Enrichment analysis pointed squarely at the Toll-like receptor and NF-κB signalling pathways, both significantly dampened, along with the LPS-sensing receptors LBP, CD14 and TLR4. Western blotting confirmed the mechanism at the protein level: LPS normally drives up TLR4 expression and phosphorylates the NF-κB subunit p65, igniting inflammation, but the cord blood exosomes reversed both effects without changing total p65 levels. Under inflammatory conditions, LPS alone suppressed mineral nodule formation, yet exosome treatment restored osteogenic differentiation—demonstrating that the vesicles protect bone formation precisely by disarming the bacterial sensor that would otherwise block it.

The implications reach beyond dentistry. Because TLR4/NF-κB signalling is a master regulator of inflammatory bone loss in many contexts, a cell-free, off-the-shelf vesicle therapy that suppresses it while delivering osteogenic cues could in principle be adapted to other defect types. The authors are careful about nomenclature, noting that under the MISEV2023 guidelines their ultracentrifugation-isolated particles are technically small extracellular vesicles, and that the active cargo—possibly exosomal microRNAs—remains to be pinned down. Limitations also include the usual gap between rat models and human periodontal pathology, unresolved donor variability and manufacturing standardisation, and the need for loss-of-function experiments with pathway inhibitors to confirm the mechanism rigorously.

Even so, the study offers a unusually complete proof of concept: a material that is injectable, sets in seconds under a dental-grade blue light, holds its mechanical ground in the mouth, releases its cargo over three weeks, quiets a destructive inflammatory pathway, and measurably regrows bone. If the results translate to larger animal models and eventually to patients, the humble contents of discarded cord blood, packaged in a photocured gel, could become a genuinely regenerative alternative to the drill-and-antibiotics cycle that currently defines periodontal care.

Subject of Research: Umbilical cord blood exosome-loaded hydrogel therapy for periodontal bone regeneration via TLR4/NF-κB signalling

Article Title: Injectable Hydrogel Loaded With Umbilical Cord Blood‐Derived Exosomes Promotes Periodontal Bone Regeneration via the TLR4/NF‐κB Signalling Pathway

Article References: Zhu, D., Liu, M., Fan, Y., Lang, L., Luo, X., Zhang, Z., Shen, Z., & Liu, H. (2026). Injectable Hydrogel Loaded With Umbilical Cord Blood‐Derived Exosomes Promotes Periodontal Bone Regeneration via the TLR4/NF‐κB Signalling Pathway. Journal of Cellular and Molecular Medicine, 30(19), Article e71347. https://doi.org/10.1111/jcmm.71347

Image Credits: AI Generated

DOI: 10.1111/jcmm.71347

Keywords: periodontitis, exosomes, umbilical cord blood, hydrogel, bone regeneration, TLR4, NF-κB, GelMA, alginate, mesenchymal stem cells, extracellular vesicles, inflammation